REVE TECHNOLOGIES, INC. (Form: 8-K, Received: 04/25/2016 11:59:20)

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 8-K

CURRENT REPORT

PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

Date of Report (Date of earliest event reported): February 19, 2016

REVE TECHNOLOGIES, INC.

(Exact name of Company as specified in its charter)



Nevada	000-54497	27-2571663
(State or other jurisdiction	(Commission File Number)	(IRS Employer
of Incorporation)		Identification Number)
	300 S El Camino Real San Clemente, California 92672
	(Address of principal executive offices)
	Phone: (714) 907-1241
	(Company ’ s Telephone Number) 17011 Beach Boulevard, Suite 900 Huntington Beach, California 92647

(Registrant’s Previous Address)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the Company under any of the following provisions:

☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

The number of issued and outstanding shares of Common Stock as at February 22, 2016, is 1,251,189,865

ITEM 1.01 ENTRY INTO A MATERIAL DEFINITIVE AGREEMENT

Effective April 19, 2016 the Registrant and certain preferred shareholders of the Registrant entered into a Purchase and Sale Agreement (the “Purchase Agreement”) with Canteck Pharma, Inc., a Delaware corporation (“Canteck” or“CKPH”) and certain majority shareholders of CKPH. Canteck has developed and has patented technology (US 8,067,531 B2) and also known as Irreversible Pepsin Fraction (“IPF”). IPF is a therapeutic platform technology that can be used to facilitate a broad range of applications. It is free from neurological, gastrointestinal and hematological side effects. IPF has not shown to be subject to viral resistance and is cost effective.

The Purchase Agreement sets forth the plan through which the Registrant purchases from Seller, on the terms and conditions set forth in the Purchase Agreement, Sellers One Hundred Percent (100%) ownership Interest in CanTeck Pharma for its current and planned operations for the country of Mexico (“CPMO”) and the exclusive Sub Licensing Agreement therewith for Irreversible Pepsin Fraction specific to the Cancer indication only, for the entire country of Mexico (the “License”); Registrant. As consideration for the Purchase, the shareholders of Canteck and or Canteck per its directive will receive controlling interest through acquiring herewith 667,000 of Registrants Series B preferred shares, to be amended to be non-dilutable, along with an amount of shares related of the purchase of the Exclusive Sub License equal to 60% of the then-issued and outstanding common stock of the Company, also to be non-dilutable. On the Closing Date Registrant shall also assume for its exclusive Sub Licensing Agreement aportion of the total liabilities due under the Exclusive Master Licensing Agreement by Canteck to the Zhabilov Trust in the allocated amount comprised of a $500,000 fee and $100,000 of other liabilities, the resulting total amountof Six Hundred Thousand ($600,000.00) US Dollars...The exclusive sub Licensing Agreement is for Irreversible Pepsin Fraction specific to the Cancer indication only, for the entire country of Mexico, or officially known as the United Mexican States.

ITEM 2.01 COMPLETION OF ACQUISITION OR DISPOSITION OF ASSETS

See Item 1.01 above.

ITEM 3.02 UNREGISTERED SALES OF EQUITY SECURITIES

Securities Issued (Preferred Shares)

On April 19, 2016, the Company issued 667,000 shares of Series B Voting Preferred Stock to Canteck Pharma, Inc. representing 66.7% of the total issued and outstanding shares of the Company’s Series B Voting Preferred Stock.

Each share of Series B Voting Preferred Stock is equal to and counted as 1,000 times the vote of all of the shares of the Corporation (i) common stock, and (ii) other voting preferred stock issued and outstanding on the date of each and every vote or consent of the shareholders of the Company regarding each and every matter submitted to the shareholders of the Company for approval.

Consideration

The consideration for the 1,000,000 shares of Series B Voting Preferred Stock was in behalf of certain of the terms of the Purchase Agreement with Canteck Pharma, Inc. described herein. See also Exhibit 10.1 to this Current Report.

Exemption from Registration

The 1,000,000 shares of the Series B Voting Preferred Stock were issued in reliance upon that exemption from the registration and prospectus delivery requirements of the Securities Act of 1933, as amended (the “Act”), specified by the provisions of Section 4(2) of the Act regarding transactions by an issuer not involving a public offering of securities. The issuance of those shares as conversion of the Indebtedness did not involve any public offering of securities.

Securities Issued (Common Shares)

On January 14, 2016, Blackbridge Capital, LLC converted a portion of a Convertible Promissory Note wherein 69,500,000 shares of the Company’s Common Stock were issued, representing 7.557% of the issued and outstanding shares of Common Stock.

On January 14, 2016, RDW Capital, LLC converted a portion of a Convertible Promissory Note wherein 32,500,000 shares of the Company’s Common Stock were issued, representing 3.534% of the issued and outstanding shares of Common Stock.

On January 14, 2016, Southridge Partners II, LP converted a portion of a Convertible Promissory Note wherein 46,221,000 shares of the Company’s Common Stock were issued, representing 5.026% of the issued and outstanding shares of Common Stock.

On January 19, 2016, JMJ Financial converted a portion of a Convertible Promissory Note wherein 38,400,000 shares of the Company’s Common Stock were issued, representing 4.008% of the issued and outstanding shares of Common Stock.

On January 20, 2016, Typenex Co Investment, LLC converted a portion of a Convertible Promissory Note wherein 70,100,000 shares of the Company’s Common Stock were issued, representing 6.818% of the issued and outstanding shares of Common Stock.

On January 26, 2016, Blackbridge Capital, LLC converted a portion of a Convertible Promissory Note wherein 81,238,094 shares of the Company’s Common Stock were issued, representing 6.492% of the issued and outstanding shares of Common Stock.

On January 26, 2016, RDW Capital, LLC converted a portion of a Convertible Promissory Note wherein 40,000,000 shares of the Company’s Common Stock were issued, bringing the total of its beneficial ownership to 3.196% of the issued and outstanding shares of Common Stock.

On January 26, 2016, Southridge Partners II, LP converted a portion of a Convertible Promissory Note wherein 101,828,800 shares of the Company’s Common Stock were issued, representing 8.138% of the issued and outstanding shares of Common Stock.

Consideration

The consideration for the shares of Common Stock issued were presentation of a Notice of Conversion relative to a Convertible Promissory Note(s).

On April 19, 2016, One Hundred Seventy Two Million Thirty Nine Thousand Three Hundred and Three (172,039,303) shares of the Company’s Common Restricted Stock were agreed to be issued to Mr. Dennis Alexander, representing 4.95% of the issued and outstanding shares of Common Stock, in exchange for the return of 333,500 shares of his Series B Voting Preferred Stock toward the Registrants Purchase Agreement with Cantech Pharma, Inc. and retains 166,500 of Series B Voting Preferred Stock. The shares shall have non dilutable provisions.

On April 19, 2016, One Hundred Seventy Two Million Thirty Nine Thousand Three Hundred and Three (172,039,303) shares of the Company’s Common Restricted Stock were agreed to be issued to Mrs. Joanne M. Sylvanus, representing 4.95% of the issued and outstanding shares of Common Stock, in exchange for her return of 333,500 shares of her Series B Voting Preferred Stock toward the Registrants Purchase Agreement with Cantech Pharma, Inc. The shares shall have non dilutable provisions.

On April 19, 2016, Two Billion Two Hundred Twenty Million Eight Hundred Sixty Three Thousand Four Hundred and Four (2,220,863,404) shares of the Company’s Common Restricted Stock were agreed to be issued to Canteck Pharma, Inc., representing 54.05% of the issued and outstanding shares of Common Stock, in behalf of the Purchase Agreement with Cantech. The shares shall have non dilutable provisions.

On April 19, 2016, Six Hundred and Sixty Seven Thousand, (667,000) shares of the Registrants Series B Voting Preferred Stock toward the Registrants Purchase Agreement were agreed to be issued to Canteck Pharma, Inc.., representing 66.7% of the issued and outstanding shares of Series B Voting Preferred Stock, in behalf of the Purchase Agreement with Cantech. The shares shall have non dilutable provisions.

Exemption from Registration

The shares of Common Stock issued pursuant to Convertible Promissory Notes were issued in reliance upon that exemption from the registration and prospectus delivery requirements of the Securities Act of 1933, as amended (the “Act”), specified by the provisions of Section 4(2) of the Act regarding transactions by an issuer not involving a public offering of securities. The issuance of those shares as conversion of the Indebtedness did not involve any public offering of securities.

Additional Issuances from Convertible Promissory Notes

Additionally, during the period commencing January 14, 2016 through January 26, 2016 and unchanged through April 22, 2016, the Company issued 479,787,894 common shares to reduce debt on certain convertible promissory notes. The issued and outstanding common shares of the Company, at the beginning of the period commencing January 14, 2016, was 771,401, 971 shares.

Exemption from Registration

The Company claims an exemption from the registration requirements of the Securities Act of 1933, as amended (the “Act”) for the private placement of these securities pursuant to Section 4(2) of the Act and/or Rule 506 of Regulation D promulgated thereunder since, among other things, the transaction does not involve a public offering, the Investor is an “accredited investor” and/or qualified institutional buyer, the Investor has access to information about the Company and its investment, the Investor will take the securities for investment and not resale, and the Company is taking appropriate measures to restrict the transfer of the securities.

ITEM 5.01 CHANGES IN CONTROL OF REGISTRANT

The information set forth and incorporated by reference in Item 3.02 of this Current Report on Form 8-K is incorporated by reference into this Item 5.01.

Identity of the person who acquired control; date and description of the transaction; and basis of control

On April 19, 2016, in behalf of the Registrants Purchase Agreement with Canteck Pharma, Inc. Mrs. Diana Zhabilov was appointed as Chairman, Mr. Harry Zhabilov was appointed as Chief Science Officer and Treasurer of the Company. Mr. Dennis Alexander continues appointment as Chief Executive Offer and Director, and Ms. Joanne M. Sylvanus continues appointment as Chief Financial Officer, Secretary and Director. It was further agreed that Valentine Dimitrov is to be appointed to the Board of Directors after the closing of the Purchase Agreement as a fifth Director.

In consideration for the terms of the Purchase Agreement between the Registrant and Cantech Pharma, Inc. which Cantech is owned by Mrs. Diana Zhabilov and who will be Chairman of the Registrant, Cantech will receive Two Billion Two Hundred Twenty Million Eight Hundred Sixty Three Thousand Four Hundred and Four (2,220,863,404) of the Registrants common restricted stock and 667,000 shares of its Preferred Series B Voting Stock. Mr. Alexander will receive 172,039,303 shares of the Company’s Common Restricted Stock and retain 166,500 shares of Voting Preferred Stock and Ms. Sylvanus will receive 172,039,303 shares of the Company’s Common Restricted Stock and retain 166,500 shares of Voting Preferred Stock in behalf of the terms of the Registrants Purchase Agreement with Canteck. These issuances will render Canteck Pharma, Inc., Mrs. Diana Zhabilov who directly owns100% of Canteck, in control of the Company.

ITEM 5.02 DEPARTURE OF DIRECTORS OR CERTAIN OFFICERS; ELECTION OF OFFICERS; APPOINTMENT OF CERTAIN OFFICERS, COMPENSATORY ARRANGEMENTS OF CERTAIN OFFICERS

The information set forth and incorporated by reference in Item 3.02 and 5.01 of this Current Report on Form 8-K is incorporated by reference into this Item 5.02.

On April 19, 2016, in behalf of the Registrants Purchase Agreement with Canteck Pharma, Inc. Mrs. Diana Zhabilov was appointed as Chairman and President of the Registrant, and Mr. Harry Zhabilov was appointed as Chief Science Officer and Treasurer of the Registrant.

It was further agreed that Valentine Dimitrov is to be appointed to the Board of Directors after the closing of the Purchase Agreement as a fifth Director. In consideration for the terms of the Purchase Agreement between the Registrant and Cantech Pharma, Inc. which Cantech is owned by Mrs. Diana Zhabilov, now acting Chairman of the Registrant, Cantech will receive 2,220,863,404 shares of the Registrants Common Restricted Stock and 667,000 shares of its Preferred Series B Voting Stock.

A description of the business experience during the past several years for our directors and executive officer is set forth below:

Mrs. Diana Zhabilov , serves as Chairman of the Registrant since April 19, 2016. Mrs. Zhabilov has served as an Educator and Clinical Instructor with Success Education Colleges from December 2014 to the present. She has worked at Dream Home Health from May 2013 to the present evaluating patients for immediate medical needs and plan of care. Education includes Board of Nursing – Sacramento, CA , Board of CNA - Sacramento, Reagan Career Institute for Phlebotomy Tech I, Golden Gate University- San Francisco, CA, College of Nursing, Medical Academy, Sofia, Bulgaria. Certifications include VN 204027, Phlebotomy and IV certified CA, CPR-BLS/AED, BSN in Nursing Diploma # 9357/1988 Sofia, Bulgaria.

Mr. Harry H. Zhabilov , Jr., BSc, McS Science serves as Chief Science Officer and Treasurer of the Registrant, and is a Vice Chairman, President and Chief Science Officer of Immunotech Laboratories, Inc. Mr. Zhabilov Founded Immunotech Laboratories, Inc. He served as Vice Chairman, Chief Science Officer and Secretary of International Technology Systems, Inc. since December 2008. Mr. Zhabilov holds a degree of B.S and M.S. in chemistry and Chemical Engineering. He is a member of ACS, ALCHE.

Dennis R. Alexander has served CEO and Director of the Registrant since April 19, 2016 having served as Chairman, CEO and Director since November 2015. He served as a Director and CEO of Boomerang Oil, Inc listed on the Canadian Securities Exchange and the Frankfurt Stock Exchange since March 2014 and as Chairman, Director, CEO, and President of the Mondial Ventures, Inc. since July 31, 2012. He has served as Chairman, CEO, and CFO of EGPI Firecreek, Inc. (“EGPI”) and President and Director of its wholly owned subsidiary Energy Producers, Inc. (“EPI”), engaged in oil and natural gas exploration, production, and development. Since May 21, 2009. Mr. Alexander served as Chairman, President and Chief Financial Officer of EGPI and Firecreek Petroleum, Inc., (“FPI”) which pursued oil and gas acquisitions internationally in certain Eurasian countries during the then trend up for oil. Since February 10, 2007 he has served as Chairman and Chief Financial Officer of EGPI and FPI since July 1, 2004 through February 9, 2007, having served as the President and Director of EGPI from May 18, 1999 to June 30, 2004. In September 1998 he was a founder, and from January 19, 1999 through its acquisition with EGPI served in various capacities as President and Director of Energy Producers Group, Inc., and was the original founding entity for EGPI and EPI. From April 1997 through March 1998 he served as CEO, Director, Consultant of Miner Communications, Inc., a media communications company. From April 26, 1997 through March, 1998 he was a director of Rockline, Inc., a private mining, resource company, and a founder of World Wide Bio Med, Inc., a private health-bio care, startup company. Since March 1996 to the present he has owned Global Media Network USA, Inc., which has included management consulting, advisory services. Mr. Alexander attended ASU studying Architecture from 1971 to 1974.

Joanne M. Sylvanus has served as a Director, Chief Financial Officer, and Secretary of the Registrant since November 2015. She served as a Director Chief Financial Officer of Boomerang Oil, Inc., listed on the Canadian Securities Exchange and the Frankfurt Stock Exchange since March 2014 and as a Director, Chief Financial Officer of Mondial Ventures, Inc since July 31, 2012 and additionally as Secretary and Treasurer since November 7, 2012. She has been engaged by EGPI Firecreek, Inc. (“EGPI”) and its wholly owned subsidiary Energy Producers, Inc. (“EPI”) which is in the business of oil and natural gas exploration, production, and development as an accounting and tax consultant since December 1999 and May 21, 1999 respectively. She is the owner and sole proprietor of J.M. Sylvanus Accounting, since May 1974, which prepares Corporate, Partnership, Trust, and Estate Tax Returns, acts as Conservator and Trustee for Estates and Trusts, and provides consulting on Financial and Tax matters. She held a Certified Public Accounting certificate from the State of Arizona from October 1972 until May 1996 when she formally retired her certificate. Over the years from 1974 until May 1996, she was the owner and sole proprietor of J.M. Sylvanus CPA which conducted certified audits for not-for-profit organizations, broker dealers, and mortgage bankers; provided tax planning and tax preparation services for business, trusts, and individuals, designed and installed business accounting systems, and sub-contracted those services with the Small Business Administration and Arizona Research Bureau. Ms. Sylvanus taught accounting at Phoenix College from 1974 through 1985. She graduated from Cleveland State University in 1970 with a B.A. in Accounting and a minor in Economics. She has served on the Board of The American Society of Women Accountants for eight years in every Board position except Secretary.

On April 19, 2016, Dennis Alexander tendered his resignation as Chairman with the Registrant in behalf of the change of control resulting from the Registrants terms of its Purchase Agreement with Canteck Pharma, Inc. Effective April 19, 2016, Mr. Dennis Alexander shall serve as Chief Executive Officer and Director, and Ms. Joanne Sylvanus as Chief Financial Officer, Secretary and Director. Mr. Alexander and Mrs. Sylvanus will each retain 166,500 shares of the Series B Voting Preferred Shares and 172,039,303 shares of the Company’s Common Restricted Stock which was in exchange for each of their return of Series B Voting Preferred Stock in the amount of 333,500. Mr. Alexander will receive a salary of Five Thousand Dollars ($5,000) per month and Ms. Slyvanus, Three Thousand Dollars ($3,000) per month.

Management and operational activities related to development of the Capital Purchase Division have been suspended at the present time due to the inability to raise the capital funding needed for both proof of test and building current or ongoing operations. This potential divisional operation will be reviewed for its potential in the future.

ITEM 5.03 AMENDMENTS TO ARTICLES OF INCORPORATION OR BYLAWS

The information set forth and incorporated by reference in 3.02, 5.01, and 5.02 of this Current Report on Form 8-K is incorporated by reference into this Item 5.03.

On November 29, 2015, the Board of Directors of Reve Technologies, Inc. (the “Company”) approved by its consent to amend the Company’s Articles of Incorporation to increase the authorized capital stock.

As a result of this filing, the Company’s Articles of Incorporation were amended to increase the total authorized capital stock from 1,000,000,000 shares to 5,000,000,000 shares consisting of (i) 4,990,000,000 shares of voting common stock, $0.001 par value per share, and (ii) 10,000,000 shares of preferred stock, $0.001 par value per shares, which remains unchanged.

For more information please see Item 5.03 and Exhibit 3.1 in our Current Report on Form 8-K filed on January 14, 2016.

ITEM 8.01 OTHER INFORMATION

Effective April 19, 2016 the Registrant and certain preferred shareholders of the Registrant entered into a Purchase and Sale Agreement (the “Purchase Agreement”) with Canteck Pharma, Inc., a Delaware corporation (“Canteck” or“CKPH”) and certain majority shareholders of CKPH. Canteck has developed and has patented technology (US 7,479,538 B2) and also known as Irreversible Pepsin Fraction (“IPF”). IPF is a therapeutic platform technology that can be used to facilitate a broad range of applications. It is free from neurological, gastrointestinal and hematological side effects. IPF has not shown to be subject to viral resistance and is cost effective.

About IPF for Cancer treatment

Immunotherapy has the potential to provide an alternative and/or complementary treatment for most types of cancer. The advantage of immunotherapy over radiation and chemotherapy is that it can act specifically against the tumor without causing normal tissue damage. Current data indicates that immune protection against all cancer requires the generation of a potent cellular immune response against a unique tumor antigen expressed by the malignant cell. As a consequence successful immune protection first requires a unique antigen expressed in the tumor cells (tumor specific antigen) and second, an induction of a potent T-cell immune response, targeted to the tumor antigen.

Unfortunately the immune system by itself can´t recognize specific tumor antigens and reject them; however recent advances have revealed that certain proteins binding with specific tumor antigens can be recognized by the immune system, this is what IPF does.

IPF proteins attach to tumor antigens, creating superantigens (Sags), which increases the number of antibodies against the malignant cells and induces a potent T-cell immune response targeted to the tumor antigen. For a stronger immune response, IPF may be paired with different kinds of adjuvants such as IL-2, IL-6, IL-12 or other cytokines. Another form of immunotherapy can also provide active immunization, which allows for amplification of the immune response. In addition, vaccines can generate a memory immune response. Recent advances have revealed that any cellular protein (expressed in virally infected cells or cancer cells) can be recognized by the immune system if those proteins are presented to the immune system in a form that results in an activation rather than ignorance or tolerance to the antigen. In addition, T-cells rather than B-cells are usually responsible for this recognition.

It is important to point out that when we discuss vaccines for cancer we are referring to treatment rather than prevention, because the antigens expressed by tumor cells (which are the immunogens recognized by the immune system) are not yet known. Attaching known proteins will increase the number of antibodies to fight against them.

This mechanism of action will give us an exact answer (known antigens we have to make known for immune system). In contrast we can use vaccines to prevent infectious diseases because the antigens expressed the causative agent – fraction and/or its proteins that can attach, serve as the immunogen are already known.

ITEM 9.01 FINANCIAL STATEMENTS AND EXHIBITS

Exhibit No.	Description
10.1	Purchase and Sale Agreement with Canteck Pharma, Inc.

SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

Reve Technologies, Inc.

Date: April 25, 2016

By: /s/Dennis Alexander

Dennis Alexander

CEO

PURCHASE AND SALE AGREEMENT BY AND BETWEEN

CANTECK PHARMA, INC.

AS SELLER

AND

REVE TECHNOLOGIES, INC.

AS BUYER

PURCHASE AND SALE AGREEMENT

This Purchase and Sale Agreement (this “Agreement”) is entered into this 19th day of April 2016, by and between, CANTECK PHARMA, INC. A Delaware Corporation, whose address is 120 W Pomona Ave., Monrovia, CA 91016. (the“Seller”, “CKPH” or the “Company”), and REVE TECHNOLOGIES, INC. (“BSSP”), a Nevada corporation, whose address is 300 S EL Camino Real, Suite 206, San Clemente, CA 92672 (“Buyer”).

Buyer and Seller may sometimes be collectively referred to herein as the “Parties” and individually as a “Party.”

RECITALS:

Seller desires to sell to Buyer and Buyer desires to purchase from Seller, on the terms and conditions set forth in this Agreement, Sellers One Hundred Percent (100%) ownership Interest in CanTeck Pharma Mexican Operations. (“CPMO”) and Exclusive Sub Licensing Agreement for Irreversible Pepsin Fraction (“IPF”) specific to the Cancer indication only for the country of Mexico (the “License”);

NOW, THEREFORE, for good and valuable consideration, the mutual benefits to be derived by each party hereunder and the mutual covenants herein contained, Seller and Purchaser agree as follows:

1.	SALE AND PURCHASE OF THE ASSETS.

1.1 Acquired Assets . Subject to the terms and conditions of this Agreement, Seller agrees to sell, convey and deliver to Buyer and Buyer agrees to purchase and acquire from Seller, Seller’s One Hundred Percent (100%) ownership Interest in CanTeck Pharma Mexican Operations. (“CPMO”) and Exclusive Sub Licensing Agreement for Irreversible Pepsin Fraction (“IPF”) specific to the CANCER indication only for Mexico (the “License”) (collectively the “Assets”) (see http://www.nationsonline.org/oneworld/map/mexico-administrative-map.htm ).

1.2 Appraisal/Valuation : A auditable master appraisal/valuation consistent with GAAP and FASB and all other regulatory guide lines and requirements shall be furnished to Buyer to assist determining the license valuation for the Country of Mexico and attached on “Annex 1” hereto.

1.3	Excluded Assets . Specifically excepted and reserved from this transaction are the following, hereinafter referred to as “Excluded Assets”:

(A)	The Company’s rights and interest to the exclusive license agreement with the Zhabilov Trust for the IPF treatment and its application to Cancer for all other regions of the World excluding the Mexican territory covered in the License for the treatment of Cancer.

(B)	All other assets of the Company not expressly included in the Acquired Assets.

1.4 Assumed Liabilities . On the Closing Date Buyer shall assume liabilities listed and attached on “Annex 2” hereto of the Licensing fee due by the Company to the Zhabilov Trust and Six Hundred Thousand US Dollars ($600,000.00) of Liabilities incurred by the Company.

1.5 Acknowledgements. Both parties acknowledge that REVE has to bring the public fillings current as well as certain accounts associated with publically traded companies (See Annex 3) which will entail expenditures by REVE of between an estimated $35,000 and $45,000 US Dollars. The Seller has no responsibility for these cost or any other accrued liabilities. The expenditures will be paid from funds raised by REVE after the Transaction.

2.	Purchase Price

2.1

Purchase Price . The purchase price for the Assets shall be Sixty percent (60%) of the common shares issued and outstanding on Reve Technologies, Inc. (the “Purchase Shares”) issued to the Seller issued at closing and the sale of Six Hundred Sixty Seven Thousand (667,000) issued and outstanding Series B Preferred Shares currently beneficially owned or held by Dennis Alexander and Joanne Sylvanus in exchange for an designated amount of the Purchase Shares listed and set fourth in Section 5. G. of this Agreement. The Purchase Shares issued to the Seller will be designated as non-dilutable. The Series B Preferred Shares sold to the Seller shall be amended to be non-dilutable.

CLOSING.

3.1

Closing . Subject to any termination pursuant to Section 8, the sale and purchase of the Assets (“Closing”) shall take place at Seller’s place of business at 120 W Pomona Ave, Monrovia, CA 91016 on or before April 28, 2016, (“Closing Date”), or at such other place and time to which the Parties may mutually agree.

3.2	Delivery by Seller . At Closing, Seller shall deliver to Buyer:

(A)	An Assignment and Bill of Sale, substantially in the form attached hereto as Exhibit 1, effecting the sale, transfer, conveyance and assignment of the One Hundred Percent ownership interest in CPMO and

(B)	The Exclusive Sub Licensing Agreement for Irreversible Pepsin Fraction (“IPF”) specific to the Cancer indication

3.3	Delivery by Buyer . At Closing, Buyer shall deliver to Seller

(A)	Two Billion Two Hundred Twenty Million Eight Hundred Sixty Three Thousand Four Hundred and Four (2,220,863,404) (the “Purchase Shares”) of REVE TECHNOLOGIES, INC.(“BSSP”) restricted common shares. The Purchase Shares are to carry a non-dilutable designation.

3.4	Further Cooperation .At the Closing and thereafter as may be necessary, Seller and Buyer shall execute and deliver such other instruments and documents and take such other actions as may be reasonably necessary to evidence and effectuate the transactions contemplated by this Agreement.

4.	REPRESENTATIONS AND WARRANTIES OF SELLER.

4.1	Seller’s Representations and Warranties . Subject to the disclosures set forth in the Exhibits referred to in this Section 7, Seller represents and warrants as to the Assets as follows:

(A)	Status . CANTECK PHARMA, INC. (“CKPH”) is a duly organized Delaware Corporation, validly existing and in good standing under the laws of the State of Delaware.

(B)

Authority . Seller owns 100% interest free and clear of any lien or encumbrance in the Assets being sold to Buyer and has the requisite power and authority to enter into this Agreement, to carry out the transactions contemplated hereby, to transfer the Assets in the manner contemplated by this Agreement, and to undertake all of the obligations of Seller set forth in this Agreement.

(C)	Validity of Obligations . This Agreement and any documents or instruments delivered by Seller at the Closing shall constitute legal, valid and binding obligations of Seller, enforceable in accordance with their terms.

(D) Litigation . There is no suit or action pending, or to the knowledge of Seller threatened, arising out of, or with respect to the ownership of the Assets.

(E) Broker’s Fees . Seller has incurred no obligation or liability, contingent or otherwise, for brokers’ or finders’ fees in respect of the matters provided for in this Agreement, and, if any such obligation or liability exists, it shall remain an obligation of Seller, and Buyer shall have no responsibility therefore.

(F) Public Filings. Seller will assist in bringing current all public filings in order to maintain a fully reporting Status within sixty (60) days of Closing and will file all necessary financial and supplemental information reports.

(G) Sales, Use, Excise, Transfer, Value added and Similar Taxes. Seller will be responsible for any such taxes imposed by any governmental agency in any jurisdiction in connection with the sale of the Acquired Assets.

(H) Registration. Seller will within 365 days of closing begin the process of filing an S- 1 registration for the Purchase Shares with the cooperation of the Buyer. Buyer may designate additional issued common shares of BSSP to be included in the registration.

(I) Acknowledgements. Seller shall procure acknowledgments by The Zhabilov Trust of the Exclusive Sub Licensing agreement and assumption of the Licensing fee and acknowledgement by CPMO of the sale of the ownership interest and assumption of the liabilities.

(J) Consents . Seller shall exercise commercially reasonable efforts to obtain all such permissions, approvals and consents by governmental authorities and others which are reasonably obtainable by Closing and are required to vest good and marketable title to the Assets in Buyer

5.	REPRESENTATIONS AND WARRANTIES OF BUYER.

Buyer’s Representations and Warranties . Buyer represents and warrants as follows:

(A)	Status of Formation . Buyer is a corporation, duly formed, validly existing and in good standing under the laws of the State of Nevada.

(B)	Authority . Buyer has the power and authority to enter into this Agreement, to carry out the transactions contemplated hereby and to undertake all of the obligations of Buyer set out in this Agreement.

(C)

Validity of Obligations . The execution, delivery and performance of this Agreement and the performance of the transactions contemplated by this Agreement will not in any respect violate, nor be in conflict with, any provision of Buyer’s governing documents, or any agreement or instrument to which Buyer is a party or is bound, or any judgment, decree, order, statute, rule or regulation applicable to Buyer (subject to governmental consents and approvals customarily obtained after the Closing). This Agreement constitutes legal, valid and binding obligations of Buyer, enforceable in accordance with its terms.

(D)	Opinion Letter of Counsel. Buyer will furnish Opinion Letter of Counsel, if necessary, for the filing of any Reports necessary to bring the Market Status to Fully Reporting. Seller will assist in procuring the opinion letter if requested by Buyer.

(E)

Board of Directors and Officers. The Board of Directors of the Company which at closing shall consist of Dennis Alexander and Joanne Sylvanus and the Board shall appoint Valentine Dimitrov, Diana Zhabilov and Harry Zhabilov to the Board of Directors for an initial six month term and appoint Diana Zhabilov Chairman and appoint Harry Zhabilov as Chief Science Officer and Treasurer of the Company. By a majority of the Board vote after close a fifth Director will be appointed for a three year term. Dennis Alexander and Joanne M. Sylvanus agree to remain as directors and officers of the Company in their current capacity.

(F)	Name Change of Buyer. A name change shall be effected within 60 days of closing.

(G)

Sale of Series B Preferred Shares by Dennis Alexander . At Closing Dennis Alexander and Joanne M. Sylvanus the owners of Five Hundred Thousand (500,000) shares each of the Series B Preferred Shares representing all the authorized shares of this class of Preferred shall cause their ownership in 667,000 these shares to be sold to Canteck Pharma, Inc. in exchange for One Hundred Seventy Two Million Thirty Nine Thousand Three Hundred and Three (172,039,303) of the Purchase shares to both Dennis Alexander and Joanne M. Sylvanus. All Purchase shares shall retain their non-duilutable designation in this initial transaction.

(H)	Broker Fee. Buyer has incurred no obligation or liability, contingent or otherwise for brokers’ or finders’ fees in respect of matters provided in this agreement and if such obligation or liability exists, it shall remain an obligation of Buyer and Seller shall have no responsibility thereof.

6. CONDITIONS PRECEDENT TO OBLIGATIONS OF BUYER . All obligations of Buyer under this Agreement are, at Buyer’s election, subject to the fulfillment, prior to or at the Closing, of each of the following conditions:

6.1 No Litigation . At the Closing, no suit, action or other proceeding shall be threatened or pending before any court or governmental agency which attempts to prevent the occurrence of the transactions contemplated by this Agreement.

6.2 Representations and Warranties . All representations and warranties of Seller contained in this Agreement shall be true in all material aspects as of the Closing as if such representations and warranties were made as of the Closing Date (except for those representations or warranties that are expressly made only as of another specific date, which representations and warranties shall be true in all material respects as of such other date) and Seller shall have performed and satisfied in all material respects all covenants and fulfilled all conditions required by this Agreement to be performed and satisfied by Seller at or prior to the Closing.

7. CONDITIONS PRECEDENT TO THE OBLIGATIONS OF SELLER . All obligations of Seller under this Agreement are, at Sellers’ election, subject to the fulfillment, prior to or at the Closing, of each of the following conditions:

7.1 No Litigation . At the Closing, no suit, action or other proceeding shall be threatened or pending before any court or governmental agency which attempts to prevent the occurrence of the transactions contemplated by this Agreement.

7.2 Representations and Warranties . All representations and warranties of Buyer contained in this Agreement shall be true in all material aspects as of the Closing, as if such representations and warranties were made as of the Closing Date (except for those representations or warranties that are expressly made only as of another specific date, which representations and warranties shall be true in all material respects as of such other date) and Buyer shall have performed and satisfied in all material respects all covenants and fulfilled all conditions required by this Agreement to be performed and satisfied by Buyer at or prior to the Closing.

8. TERMINATION AND UNWIND PROVISION.

8.1 Causes of Termination . This Agreement and the transactions contemplated here may be terminated:

A.	At any time by mutual consent of the Parties.

By either Party if the Closing shall not have occurred by May 2, 2016, despite the good faith reasonable efforts of the Parties, and if the Party desiring to terminate is not in breach of this Agreement; provided, however, such May 2, 2016 date shall not apply to any Asset for which Closing has been deferred pursuant to this Agreement.

C.	By Buyer if, on the Closing Date, any of the conditions set forth in Section 6 hereof shall not have been satisfied or waived.

D.	By Seller if, on the Closing Date, any of the conditions set forth in Section 7 hereof shall not have been satisfied or waived.

9. INDEMNIFICATION.

9.1 INDEMNIFICATION BY SELLER . UPON CLOSING, SELLER SHALL, TO THE FULLEST EXTENT PERMITTED BY LAW, RELEASE, DEFEND, INDEMNIFY, AND HOLD HARMLESS BUYER, ITS PARENT AND SUBSIDIARY COMPANIES, AND EACH OF THEIR RESPECTIVE PARTNERS, DIRECTORS, OFFICERS, EMPLOYEES, AGENTS AND OTHER REPRESENTATIVES (THE “BUYER GROUP”) FROM AND AGAINST THE FOLLOWING:

A. MISREPRESENTATIONS . ALL CLAIMS,DEMANDS,LIABILITIES, JUDGMENTS, LOSSES AND REASONABLE COSTS, EXPENSES AND ATTORNEYS’ FEES (INDIVIDUALLY A “LOSS” AND COLLECTIVELY, THE “LOSSES”) ARISING FROM THE BREACH BY SELLER OF ANY REPRESENTATION OR WARRANTY SET FORTH IN THIS AGREEMENT THAT SURVIVES CLOSING;

B. BREACH OF COVENANTS . ALL LOSSES ARISING FROM THE BREACH BY SELLER OF ANY COVENANT SET FORTH IN THIS AGREEMENT; AND

C. Notwithstanding the above, the following limitations shall apply to Seller’s indemnification obligations:

(i) Seller shall not be obligated to indemnify Buyer for any Loss unless Buyer has delivered a written notice of such Loss within a period of six (6) months after Closing (the “Survival Period”). Any Loss for which Seller does not receive written notice before the end of the Survival Period shall be deemed to be an Assumed Liability.

(ii) The indemnification obligations of Seller pursuant to this Agreement shall be limited to actual Losses and shall not include incidental, consequential, indirect, punitive, or exemplary Losses or damages;

(iii) Buyer acknowledges and agrees that the indemnification provisions in this Section 9 and the termination rights and specific performance obligations in Section 8 shall be the exclusive remedies of Buyer with respect to the transactions contemplated by this Agreement.

9.2 INDEMNIFICATION BY BUYER UPON CLOSING, BUYER SHALL TO THE FULLEST EXTENT PERMITTED BY LAW, RELEASE, DEFEND, INDEMNIFY, AND HOLD HARMLESS SELLER’S GROUP FROM AND AGAINST THE FOLLOWING:

A. MISREPRESENTATIONS . ALL LOSSES ARISING FROM THE BREACH BY BUYER OF ANY REPRESENTATION OR WARRANTY SET FORTH IN THIS AGREEMENT THAT SURVIVES CLOSING;

B. BREACH OF COVENANTS . ALL LOSSES ARISING FROM THE BREACH BY BUYER OF ANY COVENANT SET FORTH IN THIS AGREEMENT;

9.3 Notification . As soon as reasonably practical after obtaining knowledge thereof, the indemnified Party shall notify the indemnifying Party of any claim or demand which the indemnified Party has determined has given or could give rise to a claim for indemnification under this Section 9. Such notice shall specify the agreement, representation or warranty with respect to which the claim is made, the facts giving rise to the claim and the alleged basis for the claim, and the amount (to the extent then determinable) of liability for which indemnity is asserted. In the event any action, suit or proceeding is brought with respect to which a Party may be liable under this Section 9, the defense of the action, suit or proceeding (including all settlement negotiations and arbitration, trial, appeal, or other proceeding) shall be at the discretion of and conducted by the indemnifying Party. If an indemnified Party shall settle any such action, suit or proceeding without the written consent of the indemnifying Party (which consent shall not be unreasonably withheld), the right of the indemnified Party to make any claim against the indemnifying Party on account of such settlement shall be deemed conclusively denied. An indemnified Party shall have the right to be represented by its own counsel at its own expense in any such action, suit or proceeding, and if an indemnified Party is named as the defendant in any action, suit or proceeding, it shall be entitled to have its own counsel and defend such action, suit or proceeding with respect to itself at its own expense. Subject to the foregoing provisions of this Section 9, neither Party shall, without the other Party’s written consent, settle, compromise, confess judgment or permit judgment by default in any action, suit or proceeding if such action would create or attach any liability or obligation to the other Party. The Parties agree to make available to each other, and to their respective counsel and accountants, all information and documents reasonably available to them which relate to any action, suit or proceeding, and the Parties agree to render to each other such assistance as they may reasonably require of each other in order to ensure the proper and adequate defense of any such action, suit or proceeding.

10. MISCELLANEOUS

10.1 Confidentiality .

(A) Prior to Closing, to the extent not already public, Buyer shall exercise all due diligence in safeguarding and maintaining secure all engineering, geological and geophysical data, seismic data, reports and maps, the results and findings of Buyer with regard to its due diligence associated with the Assets (including without limitation with regard to due diligence associated with environmental and title matters) and other data relating to the Assets (collectively, the “Confidential Information”). Buyer acknowledges that, prior to Closing, all Confidential Information shall be treated as confidential and shall not be disclosed to third parties without the prior written consent of Seller.

(B) In the event of termination of this Agreement for any reason, Buyer shall not use or knowingly permit others to use such Confidential Information in a manner detrimental to Seller, and will not disclose any such Confidential Information to any person, firm, corporation, association or other entity for any reason or purpose whatsoever, except to Seller or to a governmental agency pursuant to a valid subpoena or other order or pursuant to applicable governmental regulations, rules or statutes.

(C) The undertaking of confidentiality shall not diminish or take precedence over any separate confidentiality agreement between the Parties. Should this Agreement terminate, such separate confidentiality agreement shall remain in full force and effect.

10.2 Notice . Any notice, request, demand, or consent required or permitted to be given hereunder shall be in writing and delivered in person or by certified letter, with return receipt requested or by prepaid overnight delivery service, or by facsimile addressed to the Party for whom intended at the following addresses:

SELLER:

CANTECK PHARMA, INC.

120 W Pomona Ave.

Monrovia, CA 91016

Attn: Diana Zhabilov

Tel: (626) 429-4948

Fax(626) 703-4172

BUYER:

REVE TECHNOLOGIES, INC.

300 S El Camino Real Suite 206

San Clemente CA 92672

Attn: Dennis Alexander

Tel: (480) 948-6581

Fax: (623) 321-1914

or at such other address as any of the above shall specify by like notice to the other.

10.3 Press Releases and Public Announcements . No Party shall issue any press release or make any public announcement relating to the subject matter of this Agreement without the prior review and prior written approval of the other Party (which approval will not be unreasonably withheld); provided, however, that any Party may make any public disclosure it believes in good faith is required by applicable law or any listing or trading agreement concerning its or its affiliates’ publicly-traded securities (in which case the disclosing Party shall use all reasonable efforts to advise the other Party, and give the other Party an opportunity to comment on the proposed disclosure, prior to making the disclosure).

10.4 Compliance with Express Negligence Test .

THE PARTIES AGREE THAT THE INDEMNIFICATION OBLIGATIONS OF THE INDEMNIFYING PARTY SHALL BE WITHOUT REGARD TO THE NEGLIGENCE OR STRICT LIABILITY OF THE INDEMNIFIED PERSON(S), WHETHER THE NEGLIGENCE OR STRICT LIABILITY IS ACTIVE, PASSIVE, JOINT, CONCURRENT OR SOLE.

10.5 Governing Law . This Agreement is governed by and must be construed according to the laws of the State of NEVADA, excluding any conflicts-of-law rule or principle that might apply the law of another jurisdiction. Any dispute under this Agreement (other than disputes regarding Title Defects and Environmental Defects) shall be submitted to the jurisdiction of the courts of the State of Nevada and venue shall be in the civil district courts of Clark County, Nevada.

10.6 Exhibits . The Exhibits attached to this Agreement are incorporated into and made a part of this Agreement. The Schedules are to be delivered at the Closing Date unless mutually agreed by the Parties in writing at the Closing Date.

10.7 Fees, Expenses, Taxes and Recording . Each Party shall be solely responsible for all costs and expenses incurred by it in connection with this transaction (including, but not limited to fees and expenses of its counsel and accountants) and shall not be entitled to any reimbursements from the other Party, except as otherwise provided in this Agreement.

10.8 Assignment . This Agreement or any part hereof may not be assigned by either Party without the prior written consent of the other Party. Subject to the foregoing, this Agreement is binding upon the Parties hereto and their respective successors and assigns.

10.9 Entire Agreement .

This Agreement constitutes the entire agreement reached by the Parties with respect to the subject matter hereof, superseding all prior negotiations, discussions, agreements and understandings, whether oral or written, relating to such subject matter.

10.10 Severability . In the event that any one or more covenants, clauses or provisions of this Agreement shall be held invalid or illegal, such invalidity or unenforceability shall not affect any other provisions of this Agreement.

10.11 Captions . The captions in this Agreement are for convenience only and shall not be considered a part of or affect the construction or interpretation of any provision of this Agreement.

10.12 Counterpart Execution . This Agreement may be executed in any number of counterparts, and each such counterpart hereof shall be deemed to be an original, and all of which together shall constitute one and the same instrument.

10.13 Waiver of Certain Damages . Each of the Parties hereby waives and agrees not to seek consequential or punitive damages with respect to any claim, controversy, or dispute arising out of or relating to this Agreement or the breach thereof.

10.14 Amendments and Waivers . This Agreement may not be modified or amended except by an instrument in writing signed by both parties. Any party hereto may, only by an instrument in writing, waive compliance by another party with any term or provision of this Agreement on the part of such other party hereto to be performed or complied with. The waiver by any party hereto of a breach of any term or provision of this Agreement shall not be construed as a waiver of any subsequent breach.

Executed as of the day and year first above written.

SELLER

CANTECK PHARMA, INC.

_____________________________

By: Diana Zhabilov

Its: President

BUYER:

REVE TECHNOLOGIES, INC.

_______________________________

By: Dennis Alexander

Its: CEO

[CONSENT ON FOLLOWING PAGE]

UNANIMOUS CONSENT OF THE BOARD OF DIRECTORS

Approved by the Board of Directors via unanimous consent, and acting pursuant to Sections 78.315 and 78.375 of the Nevada Revised Statues, further waiving herewith all notice of time, place and purposes of a meeting of the Board of Directors of the Corporation, hereby have given consent herewith, agree and confirmed to the adoption of the hereinabove listed Purchase and Sale Agreement and terms therein between Reve Technologies, Inc. (“Buyer”) and Canteck Pharma, Inc. (“Seller”) , and further confirmed by the Secretary of Reve Technologies, Inc., to be effective the 7 th day of April, 2015.

By: Jonne M. Sylvanus

Its: Director and Majority Shareholder

CFO, Secretary

By: Dennis R Alexander

Its: Director and Majority Shareholder

CEO

“EXHIBIT 1”

SECTION 3.2

(A)	Assignment and Bill of Sale, substantially in the form attached hereto as Exhibit 1, effecting the sale, transfer, conveyance and assignment of the One Hundred Percent ownership interest in CPMO and

(B)	The Exclusive Sub Licensing Agreement for Irreversible Pepsin Fraction (“IPF”) specific to the Cancer indication

[ATTACHED ON FOLLOWING PAGES WHEN COMPLETED]

“ANNEX 1”

APPRAISAL/VALUATION FOR LICENSE

To Determine

Sub License Purchased For

Entire Country of Mexico

“ANNEX 2”

Liabilities of the Company

License Fee due to Zhabilov Family Trust $500,000.00

Accounting, Merger and Acquisition Cost due to UncommonCent $100,000.00

Total $600,000.00

“ANNEX 3”

Estimated Cost to Bring Filings Current

Transfer Agent $ 1,500.00

Accounting $ 7,500.00

Edgar and XBRL Cost for December and March $ 2,500.00

Past Due Accounting Invoices $14,120.00

Past Due Legal and compliance fees $16,078.00

Total Estimated Cost $41,698.00